ArticleCureus2025
Cutaneous Metastasis of Triple Negative Breast Cancer: A Case Report and Review of Literature.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous metastases (CMs) from breast cancer are rare but represent a significant manifestation of advanced disease, occurring in a small group of patients. They often present metachronously and may resemble dermatologic conditions, complicating diagnosis. We report a 95-year-old woman with a history of ductal triple negative breast cancer (TNBC), initially treated with mastectomy and radiotherapy. Eight years post-mastectomy, she developed an erythematous and indurated skin lesion in the left axilla and one in the rachis. Histopathology confirmed metastatic carcinoma of the breast and CT scan revealed also pulmonary metastasis. Palliative treatment with topical imiquimod and supportive care was decided as the best treatment option due to the patient's very advanced age and comorbidities. The patient remains stable six months post-diagnosis. CMs indicate metastatic disease and require prompt recognition to avoid misdiagnosis. Dermatoscopy and biopsy with histological confirmation are the cornerstone tools for the diagnostic assessment. Surgical resections may be ideal for localized disease, but topical and/or systemic therapy is an effective alternative. Palliative care in combination with topical agents' administration offers symptom relief and maintains quality of life in the over elderly patients. Early recognition of CMs is crucial for accurate diagnosis and optimal management. A multidisciplinary approach ensures timely intervention, while treatment should be tailored to balance efficacy and quality of life, precisely in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.